|
By Steve Brozak
|
|
Friday, 14 November 2014 00:22 |
 What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview with The Life Sciences Report.
|
|
Read more...
|
|
By Dr. Amna Sheikh
|
|
Tuesday, 11 November 2014 11:27 |
Enanta Pharmaceutical, Inc, (NASDAQ:ENTA) recently announced that their collaborator Abbvie’s New Drug Application for an interferon-free regimen had been acknowledged by U.S. Food and Drug Administration. The NDA for acceptance of this regimen was submitted on April 21, 2014. The BioMedReports FDA Calendar shows a date for review on December 21, 2014.
|
|
Read more...
|
|
By Dr. Amna Sheikh
|
|
Tuesday, 11 November 2014 10:20 |
As you may know, POZEN Inc. (NASDAQ: POZN), gets another chance for a New Drug Application reevaluation after their previous NDA was not accepted due to the issues indicated at some stage in an inspection of the production facility creating an essential constituent necessary for the production of the firm's PA8140/PA32540 Tablets.
|
|
Read more...
|
|
By Dr. Amna Sheikh
|
|
Tuesday, 11 November 2014 10:14 |
Cubist Pharmaceuticals (NASDAQ:CBST) previously announced that new antibiotic Ceftolozane has a new drug application which is being out through the steps by the Food and Drug Administration under a priority review, moreover, the FDA has issued a drug user fee act (PDUFA) date of December 21, 2014.
|
|
Read more...
|
|
By Dr. Amna Sheikh
|
|
Tuesday, 11 November 2014 09:05 |
As you may know, BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) submitted New Drug Application with U.S Food and Drug Administration (FDA) for approval of Peramivir in U.S. The same drug has already been approved in Korea and Japan for treatment of acute influenza.
|
|
Read more...
|
|
By The Life Science Report
|
|
Monday, 10 November 2014 08:55 |
 When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted.
|
|
Read more...
|
|
By The Life Science Report
|
|
Wednesday, 05 November 2014 23:42 |
 Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very small companies.
|
|
Read more...
|
|
By M.E.Garza
|
|
Wednesday, 05 November 2014 08:35 |
 Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections.
|
|
Read more...
|
|
By David Ibrahim, MarketScanners
|
|
Monday, 03 November 2014 23:20 |
|
The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research. While the larger research entities like NCI get all the press coverage and media attention, it's the smaller highly specialized organizations working behind the scenes that are the real heroes.
|
|
Read more...
|
|
By Marilyn Mullen
|
|
Monday, 03 November 2014 20:07 |
Hope for alcohol damaged liver patients.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 9 of 56 |
